viral
atyp
pathogen
caus
type
acut
exacerb
chronic
bronchiti
clirz
microbiol
infect
consider
controversi
exist
regard
role
antibiot
manag
exacerb
chronic
obstruct
pulmonari
diseas
copd
virus
bacteria
involv
pathogenesi
mani
trial
determin
valu
antibiot
treatment
acut
exacerb
critic
patient
select
criteria
lack
control
inappropri
analysi
subject
assess
one
placebocontrol
landmark
studi
anthonisen
et
show
antibiot
therapi
shorten
durat
exacerb
prevent
deterior
especi
severest
type
worsen
dyspnea
increas
sputum
volum
purul
exacerb
moreov
recent
publish
metaanalysi
studi
use
antibiot
treatment
placebo
control
group
suggest
small
statist
signific
improv
due
antibiot
therapi
patient
exacerb
copd
editori
lancet
anthonisen
studi
howev
conclud
question
need
antibiot
treatment
exacerb
copd
still
remain
unansw
especi
assess
caus
microorgan
made
clinic
ground
alon
one
unabl
l
last
five
year
carri
four
studi
patient
acut
exacerb
chronic
bronchiti
collabor
chest
physician
sever
hospit
netherland
tabl
definit
american
thorac
societi
chronic
bronchiti
use
studi
patient
severest
form
type
exacerb
accord
anthonisen
et
includ
mean
age
patient
year
patient
pneumonia
exclud
analysi
follow
collect
purul
sputum
bacteri
cultur
blood
sampl
obtain
first
third
visit
day
serolog
determin
antibodi
respiratori
pathogen
influenza
virus
b
parainfluenza
virus
respiratori
syncyti
viru
adenoviru
chlamydia
psittaci
mycoplasma
pneumotzia
chlamydia
pntrumonia
legionella
pneumoplzila
coxiella
burnetii
determin
test
done
complementfix
assay
chlamydia
genusspecif
enzym
inmiunoassay
l
pnetcrrzophila
latex
agglutin
enzym
ininiunoassay
respiratori
syiicytialviruy
dseroloq
perform
patient
budget
reason
pathogen
assum
patient
least
fourfold
rise
antibodi
titer
igm
respons
overal
evid
viral
atyp
pathogen
caus
infect
found
patient
viral
caus
found
posit
serolog
atyp
pathogen
document
time
patient
two
patient
viral
atyp
pathogen
caus
infect
largest
studi
could
establish
correl
erad
pathogen
clinic
cure
rate
infect
somewhat
lower
report
past
unselect
patient
type
assum
less
sever
case
type
virus
play
import
role
remark
lower
comparison
studi
nicholson
et
al
younger
patient
mean
age
year
asthma
use
new
method
polymeras
chain
reaction
pcr
identifi
rhinovirus
coronavirus
recent
studi
netherland
institut
primari
health
care
nivel
use
method
identifi
pathogen
influenzalik
ill
addit
patient
pathogen
could
identifi
unpublish
observ
therefor
conclud
viral
atyp
caus
sought
studi
exclud
corona
virus
rhinovirus
uncommon
caus
type
exacerb
howev
new
studi
severest
form
exacerb
type
use
p
c
r
well
viral
cultur
need
microbiol
infect
uk
clinician
oblig
take
part
clinic
audit
defin
systemat
critic
review
qualiti
medic
care
includ
procedur
use
diagnosi
treatment
use
resourc
result
outcom
pressur
cost
contain
competit
intensifi
attent
given
qualiti
care
clinic
microbiologist
import
role
mainten
improv
qualiti
patient
care
contribut
diagnosi
manag
prevent
infect
histor
much
emphasi
place
assur
qualiti
diagnost
activ
within
clinic
laboratori
particularli
technic
expertis
voluntari
compulsori
arrang
assess
assur
compet
scientif
technic
procedur
carri
warn
mani
laboratori
may
run
parallel
intern
qualiti
assur
scheme
period
extern
review
laboratori
profici
use
basi
formal
accredit
mani
countri
cover
one
aspect
diagnost
cycl
albeit
import
one
accredit
qualiti
